Fosamax Cases to Face Causation, Preemption Challenges, Merck Says



DOCUMENTS
  • Position Statement


NEW YORK - Plaintiffs asserting claims for jaw necrosis caused by ingesting Fosamax face major hurdles in proving their cases against Merck, according to a brief the drug maker filed recently in federal court. In Re: Fosamax Products Liability Litigation, MDL No. 1789 (S.D. N.Y.).

Merck says in a Nov. 21 position statement that it expects the evidence to show that the majority of plaintiffs alleging injuries caused by Fosamax, which belongs to a class of drugs used to treat osteoporosis called bisphosphonates, likely developed osteonecrosis of the jaw because of poor oral hygiene and were being treated with other …






UPCOMING CONFERENCES




HarrisMartin's Mass Tort Settlements Conference - Sponsored by Milestone

June 27, 2024 - Buffalo, NY
The Richardson Hotel Buffalo

MORE DETAILS



HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates

May 29, 2024 - Salt Lake City, UT
The Grand America Hotel

MORE DETAILS